This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
HealthdirectFree Australian health advice you can count on.
INN: denosumab
Data updated: 2026-04-25
Available in:
🇨🇿🇬🇧🇵🇹
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
Sandoz GmbH
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
ATC Code
M05BX04
Source
EMA · EMEA/H/C/005964
(
ARTG
)
The treatment of osteoporosis in postmenopausal women. JUBBONTI significantly reduces the risk of vertebral, non-vertebral and hip fractures.,Treatment to increase bone mass in men with osteopaenia receiving androgen deprivation therapy for non-metastatic prostate cancer (see section 5.1 Pharmacodynamic properties, Clinical trials).,Treatment to increase bone mass in men with osteoporosis at increased risk of fracture.,Treatment to increase bone mass in women and men at increased risk of fracture due to long-term systemic glucocorticoid therapy.
⚠️ Warnings
• Caution should be exercised in patients with history of kidney impairment, anemia, low blood calcium, any allergy, who are taking other medications, thyroid or kidney disease, infection, during pregnancy and breastfeeding.
• In some patients, this medication may cause jawbone problems.
♦
Patient may develop Osteonecrosis of the Jaw (ONJ) with the following symptom: gum lesions. If it is so consult with your healthcare provider immediately.
